Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Benserazide . HCl

Peripheral decarboxylase inhibitor
BML-EI165-1000 1 g 70.00 USD
Do you need bulk/larger quantities?
Replaces Prod. #: ALX-550-320

Peripheral decarboxylase inhibitor. Also inhibits tryptophan hydroxylase and tyrosine hydroxylase. Used with L-DOPA as a Parkinson’s disease therapeutic.

Product Details

Formula:C10H15N3O5 . HCl
Appearance:Tan solid.
Solubility:Soluble in water. Almost insoluble in 100% ethanol, insoluble in acetone.
Shipping:Ambient Temperature
Long Term Storage:Ambient
Use/Stability:Product is subject to oxidation. Make solutions fresh daily. Store, as supplied, at room temperature for up to 1 year.
Handling:Protect from light.
Regulatory Status:RUO - Research Use Only
Please mouse over

Product Literature References

In vitro cardiac pharmacology of the new histamine H2-receptor agonist amthamine: comparisons with histamine and dimaprit: E. Poli et al.; Agents Actions 40, 44 (1993), Abstract;
The new potent and selective histamine H2 receptor agonist amthamine as a tool to study gastric secretion: G. Coruzzi et al.; Naunyn Schmiedebergs Arch. Pharmacol. 348, 77 (1993), Abstract;
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease: M.-H. Marion et al.; Adv. Neurol. 45, 493 (1987), Abstract;
Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy: D.M. Richards et al.; Drugs 28, 38 (1984), Abstract;
In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole: P.M. Laduron et al.; Mol. Pharmacol. 21, 294 (1982), Abstract;
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism: R.M. Pinder et al.; Drugs 11, 329 (1976), Abstract;

Related Literature

Download as PDF

All new literature pieces